Skip to main content
Premium Trial:

Request an Annual Quote

Exagen Diagnostics Raises $7M in Series B Private-Equity Round

NEW YORK, June 28 (GenomeWeb News) - Exagen Diagnostics has raised $7 million in a Series B round of private-equity financing, the company said today. 

 

Tullis-Dickerson led the round, while vSpring Capital and Wasatch Venture Fund participated. As GenomeWeb News has reported, Exagen completed a $5.7 million Series A round in early 2004 with the same group of investors.

 

Exagen, based in Albuquerque, NM, uses computational methods to develop genomic markers. It is currently validating prognostic marker sets for breast cancer and hepatitis C that aim to guide treatment decisions.

 

The company said its first test will be the Key2 Breast Cancer Prognosis panel, which is designed to detect changes in DNA copy number in both hormone receptor-positive and hormone receptor-negative tumors.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.